Vitamin D and spondyloarthritis

References

• Cutolo M, Otsa K, Laas K, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: northern versus Southern Europe. Clin Exp Rheumatol 2006;24(6):702-4
   PubMed Web of Science ®Google Scholar
• Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 2004;50(1):72-7
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Bellan M, Carda S, et al. Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. Rheumatol Int 2012;32(11):3365-72
   PubMed Web of Science ®Google Scholar
• Touma Z, Eder L, Zisman D, et al. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care Res (Hoboken) 2011;63(10):1440-7
   PubMed Web of Science ®Google Scholar
• Durmus B, Altay Z, Baysal O, Ersoy Y. Does vitamin D affect disease severity in patients with ankylosing spondylitis? Chin Med J (Engl) 2012;125(14):2511-15
   PubMed Web of Science ®Google Scholar
• Guillot X, Semerano L, Saidenberg-Kermanac’h N, et al. Vitamin D and inflammation. Joint Bone Spine 2010;77:552-7
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013;45(2):256-66
   PubMed Web of Science ®Google Scholar
• Pludowski P, Holick MF, Pilz S, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 2013;12(10):976-89
   PubMed Web of Science ®Google Scholar
• Obermayer-Pietsch BM, Lange U, Tauber G, et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 2003;14:995-1000
   PubMed Web of Science ®Google Scholar
• Mosaad YM, Hammad EM, Fawzy Z, et al. Vitamin D receptor gene polymorphism as possible risk factor in rheumatoid arthritis and rheumatoid related osteoporosis. Hum Immunol 2014;75(5):452-61
   PubMed Web of Science ®Google Scholar
• Jung KH, Kim TH, Sheen DH, et al. Associations of vitamin d binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. J Rheumatol 2011;38:2224-9
   PubMed Web of Science ®Google Scholar
• Steinwender G, Lindner E, Weger M, et al. Association between polymorphism of the vitamin D metabolism gene CYP27B1 and HLA-B27-associated uveitis. Is a state of relative immunodeficiency pathogenic in HLA B27-positive uveitis? PLoS One 2013;8(4):e62244
   PubMed Web of Science ®Google Scholar
• Fischer R, Trudgian DC, Wright C, et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol Cell Proteomics 2012;11(2):M111.013904
   PubMed Web of Science ®Google Scholar
• International Genetics of Ankylosing Spondylitis Consortium (IGAS)1. Cortes A, Hadler J, Pointon JP, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 2013;45(7):730-8
   PubMed Web of Science ®Google Scholar
• Demirbilek H, Aydogdu D, Ozon A. Vitamin D-deficient rickets mimicking ankylosing spondylitis in an adolescent girl. Turk J Pediatr 2012;54:177-9
   PubMed Web of Science ®Google Scholar
• Lukik IK, Grcevic D, Kovacic N, et al. Alteration of newly induced enchondral bone formation in adult mice without tumour necrosis factor receptor 1. Clin Exp Immunol 2005;139(2):236-44
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factor-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006;45(10):1197-200
   PubMed Web of Science ®Google Scholar
• Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007;9:207
   PubMed Web of Science ®Google Scholar
• Lories RJ, Derese I, De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97
   PubMed Web of Science ®Google Scholar
• Appel H, Ruiz-Heiland G, Listing J, et al. Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis. Arthritis Rheum 2009;60(11):3257-62
   PubMed Web of Science ®Google Scholar
• Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:572-4
   PubMed Web of Science ®Google Scholar
• Haynes KR, Pettit AR, Duan R, et al. Excessive bone formation in a mouse model of ankylosing spondylitis is associated with decreases in Wnt pathway inhibitors. Arthritis Res Ther 2012;14:R253
   PubMed Web of Science ®Google Scholar
• Saad CG, Ribeiro ACM, Moraes JCB, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012;14:R216
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13(2):156-63
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol 2014;170(4):645-50
   PubMed Web of Science ®Google Scholar
• Clarke BL, Drake MT. Clinical utility of serum sclerostin measurements. Bonekey Rep 2013;2:361
   PubMedGoogle Scholar
• Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011;26(12):2812-22
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-83
   PubMed Web of Science ®Google Scholar
• Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. Journal Clin Endocrinol Metab 2010;95:5056-62
   PubMed Web of Science ®Google Scholar
• Szulc P, Bertholon C, Borel O, et al. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res 2013;28:855-64
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013;24:489-94
   PubMed Web of Science ®Google Scholar
• Erten S, Kucuksahin O, Sahin A, et al. Decreased plasma vitamin D levels in patients with undifferentiated spondyloarthritis and ankylosing spondylitis. Intern Med 2013;52(3):33-44
   Web of Science ®Google Scholar
• Memerci Baskan B, Dogan YP, Sivas F, et al. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 2010;30(3):375-81
   PubMed Web of Science ®Google Scholar
• Muntean LM, Simon SP, Font P, et al. Vitamin D deficiency in men with ankylosing spondylitis. Ann Rheum Dis 2011;70(Suppl 3):334
   PubMedGoogle Scholar
• Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993;52(5):343-6
   PubMed Web of Science ®Google Scholar
• Durmus B, Altay Z, Baysal O, Ersoy Y. Does vitamin D affect disease severity in patients with ankylosing spondylitis? Chin Med J (Engl) 2012;125(14):2511-15
   PubMed Web of Science ®Google Scholar
• Lange U, Jung O, Teichmann J, Neeck G. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormon in ankylosing spondylitis. Osteoporos Int 2001;12:1031-5
   PubMed Web of Science ®Google Scholar
• Lange U, Teichmann J, Strunk J, et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005;16(12):1999-2004
   PubMed Web of Science ®Google Scholar
• Arends S, Spoorenberg A, Bruyn GA, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporosis Int 2011;22(5):1431-9
   PubMed Web of Science ®Google Scholar
• Rostom S, Gossec L, Kolta S, et al. Prevalence of vitamin D deficiency in spondyloarthropathy. Ann Rheum Dis 2009;68(Suppl 3):648
   PubMedGoogle Scholar
• Hmamouchi I, Paternotte S, Borderie D, et al. Vitamin D deficiency is associated with a more active and severe disease in early axial spondyloarthritis: data from the DESIR cohort. 77th Annual Meeting of the American College of Rheumatology/ 48th Annual Meeting of the Association of Rheumatology Health Professionals, San Diego, CA, 25–30 October 2013. Arthritis Rheum 2013. 65 (Suppl 10):S649
   Google Scholar
• Yazmalar L, Ediz L, Alpayci M, et al. Seasonal disease activity and serum vitamin D levels in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. Afr Health Sci 2013;13(1):47-55
   PubMed Web of Science ®Google Scholar
• Hmamouchi I, Allali F, Hamdaoui B. The relation between disease activity, vitamin D levels and bone mineral density in men patients with ankylosing spondylitis. Rheumatol Rep 2013;5:e3-7-11
   Google Scholar
• Baykal T, Alp F Ugur M. The correlation between serum vitamin D levels and parathyroid hormone and disease activity in patients with ankylosing spondylitis. Osteoporosis Int 2011;22:937-41X
   Web of Science ®Google Scholar
• Braun-Moscovici Y, Toledano K, Markovits D, et al. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int 2011;31(4):493-9
   PubMed Web of Science ®Google Scholar
• Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late ankylosing spondylitis. Am J Med 1997;103(3):233-41
   PubMed Web of Science ®Google Scholar
• Teichmann J, Voglau MJ, Lange U. Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis. Rheumatol Int 2010;30(12):1559-63
   PubMed Web of Science ®Google Scholar
• Zhao S, Duffield SJ, Moots RJ, Goodson NJ. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology (Oxford) 2014;53(9):1595-603
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Bellan M, Nerviani A, et al. Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis d in patients with inflammatory/autoimmune rheumatic diseases. J Rheumatol 2013;40(2):166-72
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Bellan M, Antonini G, et al. Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: implications for vitamin D supplementation. Rheumatology (Oxford) 2011;50(12):2290-6
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. NEngl JMed 2007;357:266-81
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010;21(7):1121-32
   PubMed Web of Science ®Google Scholar
• Meyer O, Dawidowicz K, Wabo S. L’Actualité rhumatologique. Elsevier Masson Publishing; Paris, France: 2011. p. 243
   Google Scholar
• Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3 : a pilot study. Arthritis Rheum 1990;33(11):1723-7
   PubMedGoogle Scholar
• Wendling D, Prati C. Spondyloarthritis and smoking: towards a new insight into the disease. Expert Rev Clin Immunol 2013;9:511-16
   PubMed Web of Science ®Google Scholar
• Tang X, Pan Y, Zhao Y. Vitamin D inhibits the expression of interleukin-8 in human periodontal ligament cells stimulated with Porphyromonas gingivalis. Arch Oral Biol 2013;58(4):397-407
   PubMed Web of Science ®Google Scholar
• Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 1984;74(2):657-61
   PubMed Web of Science ®Google Scholar
• Rigby WF, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984;74(4):1451-5
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998;101(1):252-62
   PubMed Web of Science ®Google Scholar
• Hewison M, Freeman L, Hughes SV, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 2003;170:5382-90
   PubMed Web of Science ®Google Scholar
• Fritsche J, Mondal K, Ehrnsperger A, et al. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003;102(9):3314-16
   PubMed Web of Science ®Google Scholar
• Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007;8:285-93
   PubMed Web of Science ®Google Scholar
• Daniel C, Sartory NA, Zahn N, et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23-33
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol 2014;57(1):38-43
   PubMed Web of Science ®Google Scholar
• Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014;57(1):28-37
   PubMed Web of Science ®Google Scholar
• Dong H, Li Q, Zhang Y, et al. IL23R gene confers susceptibility to ankylosing spondylitis concomitant with uveitis in a Han Chinese population. PLoS One 2013;8(6):e67505
   PubMed Web of Science ®Google Scholar
• Kadi A, Costantino F, Izac B, et al. Brief report: the IL23R nonsynonymous polymorphism rs 11209026 is associated with radiographic sacroiliitis in spondyloarthritis. Arthritis Rheum 2013;65(10):2655-60
   PubMedGoogle Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009;60(9):2633-43
   PubMed Web of Science ®Google Scholar
• Ciccia F, Accardo-Palumbo A, Rizzo A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2014;73(8):1566-74
   PubMed Web of Science ®Google Scholar
• Van Praet L1, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72(3):414-17
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009;60(4):955-65
   PubMed Web of Science ®Google Scholar
• Benham H, Rehaume LM, Hasnain SZ, et al. Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol 2014;66(7):1755-67
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18(7):1069-76
   PubMed Web of Science ®Google Scholar
• Donate-Correa J, Dominguez-Pimentel V, Mendez-Perez ML, et al. Selective vitamin D receptor activation as an anti-inflammatory target in chronic kidney disease. Mediators Inflamm 2014;2014:670475
   PubMed Web of Science ®Google Scholar
• Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett 2010;131(1):49-58
   PubMed Web of Science ®Google Scholar